NetworkNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Releases Positive Results from PK Bridging Study, Anticipates Development in Japan and China
Tonix Pharmaceuticals (NASDAQ: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, is reporting positive results from its clinical pharmacokinetic (“PK”) bridging study of Tonmya(TM). The study evaluated the efficacy of Tonmya, also known as TNX-102 SL (cyclobenzaprine HCl sublingual tablets), in healthy adult male and female ethnic Japanese and Chinese volunteers. The report noted that Tonmya was generally well tolerated in the ethnic Japanese and Chinese healthy volunteers. Tonix holds issued patents for market exclusivity rights of Tonmya in Japan, China, Hong Kong and Taiwan.” “This bridging study is an important first step as we…







